Centessa Pharmaceuticals Statistics

Total Valuation

LON:0ACX has a market cap or net worth of GBP 4.50 billion. The enterprise value is 4.38 billion.

Market Cap	4.50B
Enterprise Value	4.38B

Important Dates

The next estimated earnings date is Tuesday, August 4, 2026.

Earnings Date	Aug 4, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+14.73%
Shares Change (QoQ)	+8.15%
Owned by Insiders (%)	0.64%
Owned by Institutions (%)	55.72%
Float	97.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	12.18
P/TBV Ratio	12.18
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-23.07
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-27.64

Financial Position

The company has a current ratio of 9.53, with a Debt / Equity ratio of 0.24.

Current Ratio	9.53
Quick Ratio	9.11
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	-0.56
Interest Coverage	-22.69

Financial Efficiency

Return on equity (ROE) is -57.38% and return on invested capital (ROIC) is -28.92%.

Return on Equity (ROE)	-57.38%
Return on Assets (ROA)	-27.43%
Return on Invested Capital (ROIC)	-28.92%
Return on Capital Employed (ROCE)	-42.41%
Weighted Average Cost of Capital (WACC)	11.11%
Revenue Per Employee	n/a
Profits Per Employee	-1.61M
Employee Count	118
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, LON:0ACX has paid 963,292 in taxes.

Income Tax	963,292
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +221.75% in the last 52 weeks. The beta is 1.26, so LON:0ACX's price volatility has been higher than the market average.

Beta (5Y)	1.26
52-Week Price Change	+221.75%
50-Day Moving Average	33.67
200-Day Moving Average	25.27
Relative Strength Index (RSI)	70.03
Average Volume (20 Days)	1,435

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-194.39M
Pretax Income	-188.85M
Net Income	-189.81M
EBITDA	-194.13M
EBIT	-194.39M
Earnings Per Share (EPS)	-1.35

Full Income Statement

Balance Sheet

The company has 209.46 million in cash and 89.22 million in debt, with a net cash position of 120.24 million.

Cash & Cash Equivalents	209.46M
Total Debt	89.22M
Net Cash	120.24M
Net Cash Per Share	n/a
Equity (Book Value)	369.07M
Book Value Per Share	2.39
Working Capital	236.36M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -158.12 million and capital expenditures -280,960, giving a free cash flow of -158.40 million.

Operating Cash Flow	-158.12M
Capital Expenditures	-280,960
Depreciation & Amortization	251,994
Net Borrowing	n/a
Free Cash Flow	-158.40M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0ACX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.73%
Shareholder Yield	-14.73%
Earnings Yield	-4.22%
FCF Yield	-3.52%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1